US20100093667A1 - Salts of hiv inhibitor compounds - Google Patents

Salts of hiv inhibitor compounds Download PDF

Info

Publication number
US20100093667A1
US20100093667A1 US12/499,018 US49901809A US2010093667A1 US 20100093667 A1 US20100093667 A1 US 20100093667A1 US 49901809 A US49901809 A US 49901809A US 2010093667 A1 US2010093667 A1 US 2010093667A1
Authority
US
United States
Prior art keywords
salt
hydrate
pharmaceutical composition
fluoro
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/499,018
Other languages
English (en)
Inventor
Benjamin R. Graetz
Richard Polniaszek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to US12/499,018 priority Critical patent/US20100093667A1/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POLNIASZEK, RICHARD P., GRAETZ, BENJAMIN R.
Publication of US20100093667A1 publication Critical patent/US20100093667A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the invention relates generally to salts of compounds with antiviral activity and more specifically with anti-HIV properties.
  • HIV Human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • Inhibitors of HIV are useful to treat HIV infection in a mammal (e.g., reduce and limit the establishment and progression of infection by HIV) as well as in diagnostic assays for HIV.
  • the usefulness of currently marketed inhibitors of HIV is to some extent limited by toxicity and other side effects. Thus, there is a need for new HIV therapeutic agents.
  • a pharmaceutical formulation of a therapeutic agent must reproducibly and consistently deliver the therapeutic agent to a patient in need thereof. This consistency of delivery can be achieved, at least in part, by incorporation of a stable, soluble, solid-state form of the therapeutic agent into the pharmaceutical composition. Moreover, the synthesis of the desired solid-state form of the therapeutic agent should be technically and economically feasible, and should be suitable for full-scale commercial production.
  • Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is a reverse transcriptase inhibitor that blocks the replication of HIV viruses, in vivo and in vitro, and has limited undesirable side effects when administered to human beings.
  • Ethyl N-[(S)( ⁇ [2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is a low melting point, amorphous, solid which is difficult to isolate, purify, store for an extended period, and formulate as a pharmaceutical composition.
  • Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is also a weak base that is capable of forming salts with acids.
  • the present invention provides stable salts of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate that are more physically stable, and are more readily isolated and formulated, than the free base form of the compound.
  • the salts of the present invention are useful, for example, for treating human patients infected with human immunodeficiency virus (strains of HIV-1 or HIV-2) which causes AIDS.
  • the salts of the present invention are also useful, for example, for preparing a medicament for treating HIV or an HIV associated disorder.
  • the salts of the present invention are also useful, for example, for inhibiting the replication of HIV viruses in vitro, and can be used, therefore, in biological assays as a control compound for identifying other reverse transcriptase inhibitors, or for investigating the mechanism of action of HIV reverse transcriptase and its inhibition.
  • the present invention provides citrate, succinate and malonate salts of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate, and methods of making the foregoing salts.
  • the salts of the present invention are anhydrous, while in other embodiments the salts of the present invention are at least partially hydrated.
  • the salts of the present invention exist as crystalline forms.
  • the present invention comprises citrate, succinate and malonate salts of the compound of Formula P, as well as hydrates thereof.
  • the inventive hydrates may be in a partial (e.g., hemi-hydrate) or full hydrated state (e.g., mono-hydrate).
  • the present invention also comprises the subject salts in anhydrous or essentially anhydrous states.
  • the inventive salts and hydrates thereof comprise amorphous and crystalline states, as well as states comprising both amorphous and crystalline characteristics.
  • crystalline means a material that has an ordered, long range molecular structure. In contrast, “amorphous” materials do not possess long range order.
  • crystalline materials are generally more stable thermodynamically than amorphous forms of the same substance. Thus, with only a few notable exceptions, it is generally preferred to use crystalline materials in pharmaceutical applications.
  • a measure of the degree of crystallinity of the inventive compounds can be seen, for example, in the sharpness of the DSC and XRPD absorption bands (peaks). The sharper the peak, the higher the degree of crystallinity. Conversely, the broader the peak, the lower the degree of crystallinity.
  • a citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is characterized by absorption bands, obtained from an X-ray powder diffraction pattern, at spectral d-spacings of 4.48, 3.12 and 6.05 angstroms;
  • a succinate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is characterized by absorption bands, obtained from an X-ray powder diffraction pattern, at spectral
  • N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is characterized by absorption bands, obtained from X-ray powder diffraction pattern, at spectral d-spacings of 4.99, 5.93 and 4.72 angstroms.
  • the present invention provides a citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate having a melting point of from 142° C. to 150° C.
  • Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is an amidate prodrug which undergoes reaction with and decomposition in protic solvents. The rate of the reaction depends on pH and temperature. Consequently, the formation of a stable salt between the amidate prodrug and citric acid, succinic acid and/or malonic acid, which each contain nucleophilic moieties capable of reacting with the prodrug (e.g., reaction with the amidate moiety of the prodrug) is a surprising and unexpected result.
  • the present invention provides pharmaceutical compositions that each include a therapeutically effective amount of a salt of the present invention and a pharmaceutically acceptable carrier or excipient.
  • Pharmaceutical compositions of the present invention may also include an additional therapeutic agent, such as an antiviral, antibacterial, antifungal or anticancer agent.
  • the pharmaceutical compositions of the invention may be in the form of unit dosage forms, such as tablets or capsules.
  • the unit dosage forms typically provide an effective daily dose of a salt of the present invention to a human being in need thereof.
  • Effective daily doses of the salts of the present invention are typically from 1 mg to 100 mg, such as from 10 mg to 30 mg.
  • the present invention provides methods of making the citrate, succinate and malonate salts of the present invention.
  • the present invention provides a process for preparing a citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate, wherein the process includes the step of contacting about one equivalent of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate free base in a suitable solvent (e.g., acetonitrile) with form about one equivalent to about 1.2 equivalents of citric acid at a suitable solvent (e.
  • the present invention also provides a process for preparing a succinate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate, wherein the process includes the step of contacting about one equivalent of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate free base in a suitable solvent (e.g., 2-butanone) with from about one equivalent to about 1.2 equivalents of succinic acid at a temperature in the range of from about 60° C.
  • a suitable solvent e.g., 2-butanone
  • the present invention provides a process for preparing a malonate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate, wherein the process includes the step of contacting about one equivalent of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate free base in a suitable solvent (e.g., 2-butanone) with from about one equivalent to about 1.2 equivalents of malonic acid at a temperature in the range of from about 50° C.
  • a suitable solvent e.g., 2-butanone
  • the present invention provides methods of treating or prophylactically preventing AIDS, wherein the methods include the step of administering to a human being suffering from AIDS a therapeutically effective amount of a salt of the invention, or a hydrate thereof.
  • FIG. 1 shows a characteristic differential scanning calorimetry (DSC) trace for the malonate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • DSC differential scanning calorimetry
  • FIG. 2 shows a characteristic DSC trace for the succinate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • FIG. 3 shows a characteristic DSC trace for the citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • FIG. 4 shows a characteristic X-ray powder diffraction (XRPD) pattern for the malonate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • XRPD characteristic X-ray powder diffraction
  • FIG. 5 shows a characteristic XRPD pattern for the succinate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate
  • FIG. 6 shows a characteristic XRPD pattern for the citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • the present invention provides citrate, succinate and malonate salts of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • the citrate salt is shown in Formula I:
  • the succinate salt is shown in Formula II:
  • the malonate salt is shown in Formula III:
  • the citrate, succinate and malonate salts of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate are useful, for example, for inhibiting the replication of HIV in vitro and in vivo.
  • Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is a prodrug that is metabolized in the human body to yield a parent compound which, in turn, is phosphorylated within the body to produce the active metabolite that inhibits HIV replication.
  • Example 8 herein shows that Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate causes a greater accumulation of the active metabolite in white blood cells, which are the cells that harbor the HIV virus, than does the parent compound.
  • Example 9 herein presents in vitro data showing that Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is a more potent anti-HIV drug than the parent compound as assessed in an in vitro assay.
  • Example 10 herein provides data showing that a tablet containing the citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate provides this drug to the bloodstream of Beagle dogs with similar pharmacokinetics to a liquid preparation of the drug administered orally.
  • the citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is a physically and chemically stable composition of matter that can be administered orally to a living subject, to provide a therapeutically effective amount of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate, which is a more effective anti-HIV agent than the parent compound.
  • the present invention provides pharmaceutical compositions, also referred to as pharmaceutical formulations that include a therapeutically effective amount of one or more salts of the invention, and a pharmaceutically acceptable carrier or excipient.
  • compositions of the invention are formulated with conventional carriers and excipients, which are selected in accord with ordinary practice.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and physiologically innocuous to the recipient thereof. Tablets contain such components as excipients, glidants, fillers, binders and the like.
  • Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration they are generally isotonic. All formulations optionally contain excipients such as those set forth in the Handbook of Pharmaceutical Excipients (R. C.
  • Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like.
  • the pH of the formulations ranges from about 3 to about 11, but is ordinarily about 7 to 10.
  • the formulations may conveniently be presented in unit dosage form (e.g., tablet) and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations generally are found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, Pa.). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • compositions containing the active ingredient may be in any form suitable for the intended method of administration.
  • tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation.
  • Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable.
  • excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
  • inert diluents such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmel
  • Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium phosphate or kaolin
  • an oil medium such as peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions of salts of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients can include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate).
  • a suspending agent
  • the aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
  • Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
  • a dispersing or wetting agent e.g., sodium tartrate
  • suspending agent e.g., sodium EDTA
  • preservatives e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these.
  • Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
  • the emulsion may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • sweetening agents such as glycerol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
  • compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
  • a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils may conventionally be employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid
  • a time-release formulation intended for oral administration to humans may contain approximately 1 to 1000 mg of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total composition (weight:weight).
  • Formulations suitable for administration to the eye include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, such as sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • a flavored basis such as sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia
  • mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for intrapulmonary or nasal administration have a particle size for example in the range of 0.1 to 500 microns (including particle sizes in a range between 0.1 and 500 microns in increments of microns such as 0.5, 1, 30 microns, 35 microns, etc.), which is administered by rapid inhalation through the nasal passage or by inhalation through the mouth so as to reach the alveolar sacs.
  • Suitable formulations include aqueous or oily solutions of the active ingredient.
  • Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered with other therapeutic agents such as compounds heretofore used in the treatment or prophylaxis of conditions associated with HIV activity.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations are presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • sterile liquid carrier for example water for injection
  • Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose or an appropriate fraction thereof, of the active ingredient.
  • a daily dose of a salt of the present invention can be provided in a single tablet, or in multiple tablets (e.g., two or three tablets).
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • compositions that are also within the scope of the invention provide controlled release of the active ingredient to allow less frequent dosing or to improve the pharmacokinetic or toxicity profile of the active ingredient. Accordingly, the invention also provides pharmaceutical compositions comprising one or more salts of the invention formulated for sustained or controlled release.
  • An effective dose of a salt of the present invention depends, for example, on whether the salt is being used prophylactically (typically a lower dose is required compared to therapeutic use of the same salt), the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using conventional dose escalation studies.
  • An effective dose can be expected to be from about 0.0001 mg/kg body weight per day to about 100 mg/kg body weight per day. Typically, from about 0.01 to about 10 mg/kg body weight per day. More typically, from about 0.01 to about 5 mg/kg body weight per day. More typically, from about 0.05 to about 0.5 mg/kg body weight per day.
  • the daily dose for an adult human of approximately 70 kg body weight will typically range from 1 mg to 1000 mg, preferably between 5 mg and 500 mg, and may take the form of single or multiple doses.
  • the dose of a salt of the present invention in a unit dose formulation to be administered once per day may be from 1 mg to 100 mg, such as from 30 mg to 60 mg, such as a 30 mg daily dose or a 60 mg daily dose.
  • Each of the citrate, succinate and malonate salts of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate may be employed in combination with other therapeutic agents for the treatment or prophylaxis of AIDS and/or one or more other diseases present in a human subject suffering from AIDS (e.g., bacterial and/or fungal infections, other viral infections such as hepatitis B or hepatitis C, or cancers such as Kaposi's sarcoma).
  • the additional therapeutic agent(s) may be coformulated with one or more salts of the invention (e.g., coformulated in a tablet).
  • agents that are effective for the treatment or prophylaxis of viral, parasitic or bacterial infections, or associated conditions, or for treatment of tumors or related conditions include 3′-azido-3′-deoxythymidine (zidovudine, AZT), 2′-deoxy-3′-thiacytidine (3TC), 2′,3′-dideoxy-2′,3′-didehydroadenosine (D4A), 2′,3′-dideoxy-2′,3′-didehydrothymidine (D4T), carbovir (carbocyclic 2′,3′-dideoxy-2′,3′-didehydroguanosine), 3′-azido-2′,3′-dideoxyuridine, 5-fluorothymidine, (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU), 2-chlorodeoxyadenosine, 2-deoxycoformycin, 5-fluorouracil,
  • Suitable active therapeutic agents or ingredients which can be combined with the salts of the invention, and which have activity against HIV, include 1) HIV protease inhibitors, e.g., amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, lopinavir+ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), AG1859, DG35, L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100, 2) a HIV non-nucleoside inhibitor of reverse transcriptase, e.g., capravirine, emivirine, delaviridine, efavirenz, nevirapine
  • Ziagen (Abacavir sulfate, U.S. Pat. No. 5,034,394) Epzicom (Abacavir sulfate/lamivudine, U.S. Pat. No. 5,034,394) Hepsera (Adefovir dipivoxil, U.S. Pat. No. 4,724,233) Agenerase (Amprenavir, U.S. Pat. No. 5,646,180) Reyataz (Atazanavir sulfate, U.S. Pat. No. 5,849,911) Rescriptor (Delavirdine mesilate, U.S. Pat. No.
  • Hivid (Dideoxycytidine; Zalcitabine, U.S. Pat. No. 5,028,595) Videx (Dideoxyinosine; Didanosine, U.S. Pat. No. 4,861,759) Sustiva (Efavirenz, U.S. Pat. No. 5,519,021) Emtriva (Emtricitabine, U.S. Pat. No. 6,642,245) Lexiva (Fosamprenavir calcium, U.S. Pat. No. 6,436,989) Virudin; Triapten; Foscavir (Foscarnet sodium, U.S. Pat. No. 6,476,009) Crixivan (Indinavir sulfate, U.S. Pat. No. 5,413,999) Epivir (Lamivudine, U.S. Pat. No. 5,047,407) Combivir (Lamivudine/Zidovudine, U.S. Pat. No. 4,724,232)
  • Kaletra (Lopinavir/ritonavir, U.S. Pat. No. 5,541,206) Viracept (Nelfinavir mesilate, U.S. Pat. No. 5,484,926) Viramune (Nevirapine, U.S. Pat. No. 5,366,972) Norvir (Ritonavir, U.S. Pat. No. 5,541,206) Invirase; Fortovase (Saquinavir mesilate, U.S. Pat. No. 5,196,438) Zerit (Stavudine, U.S. Pat. No. 4,978,655) Truvada (Tenofovir disoproxil fumarate/emtricitabine, U.S. Pat. No. 5,210,085)
  • Retrovir Zadovudine; Azidothymidine, U.S. Pat. No. 4,724,232
  • the present invention provides methods of treating Acquired immune Deficiency Syndrome (AIDS), wherein each method includes the step of administering to a human being suffering from AIDS a therapeutically effective amount of a salt of the invention, or a hydrate of a salt of the invention.
  • Treatment of AIDS includes the amelioration of at least one symptom of AIDS, and/or slowing or preventing the progression of the disease.
  • the therapeutically effective amount of the salt is administered to a human being in the form of a pharmaceutical composition, as described under the heading “Pharmaceutical Compositions”.
  • the pharmaceutical composition is administered orally, for example in the form of a tablet.
  • Examples of therapeutically effective daily doses of one or more salts of the invention, or hydrates thereof, are from 1 mg to 100 mg, such as from 10 mg to 30 mg.
  • the salts of the invention can be administered daily, for example in the form of one or more tablets that include an amount of salt that provides an effective amount, such as 10 mg or 30 mg or 60 mg, of the free base when the salt dissociates in an aqueous medium within the human body.
  • One or more salts of the invention are administered by any route appropriate to the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural), and the like. It will be appreciated that the preferred route may vary with, for example, the condition of the recipient.
  • An advantage of the salts of the present invention is that they are orally bioavailable and can be dosed orally.
  • Compound (2) was synthesized according to the synthetic schemes disclosed in Tann et. al., JOC, 1985, Vol. 50 pg. 3644 and Howell et. al., JOC, 1988, Vol. 53, pg. 85.
  • Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is an amidate prodrug which undergoes decomposition in protic solvents under acidic or basic conditions. For this reason, acids with potentially nucleophilic moieties were not included in the initial round of screening.
  • citric acid includes a hydroxyl group which can act as a nucleophile toward the amidate moiety of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate and potentially undergo a reaction therewith in which a covalent bond is formed between Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate and the hydroxyl group of citric acid with the expulsion of either phenol or alanine ethyl ester.
  • Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate is amorphous, hygroscopic and chemically unstable when stored under open condition at 40° C. and 75% relative humidity (RH).
  • RH relative humidity
  • the citrate salt of Ethyl N-RS)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate was formulated into 10 mg and 30 mg tablets using the roller compaction process.
  • the active ingredient, lactose anhydrous, microcrystalline cellulose and croscarmellose sodium were first blended, the mixture was then lubricated with one third of the total amount of magnesium stearate, then roller compacted, followed by milling. The resulting granules were lubricated with the remaining amount of magnesium stearate and pressed into tablets.
  • Table 4 shows the compositor of tablets that include the citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate, and that provide either 10 mg or 30 mg of the free base form of the compound when the citrate salt dissociates in an aqueous medium.
  • the adjusted drug substance quantity will be subtracted from the quantity of anhydrous lactose.
  • the abbreviation NF means national formulary, and the abbreviation HSE means House Compendial Reference which is the internal standard used at Gilead Sciences.
  • Ethyl N-RS)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoylR-alaninate is a prodrug that is hydrolyzed in the human body to yield a hydrolysis product that is hereinafter referred to as “the parent compound”.
  • the parent compound is phosphorylated within the human body to produce a biologically active phosphorylated product (hereinafter “the active metabolite”) which inhibits the activity of reverse transcriptase enzyme.
  • lymphocyte cells were treated with either 1 ⁇ M prodrug or 100 ⁇ M parent compound for 2, 6, and 24 hours.
  • Peripheral blood mononuclear cells PBMCs were isolated from human huffy coats (Stanford Blood Bank, Palo Alto, Calif.) using centrifugation in Ficoll Paque Plus (GE Healthcare, Piscataway, N.J.) according to manufacturer's procedure.
  • PBMCs isolated from 3 to 4 independent donors were maintained in RPM1-1640 media with 20% fetal bovine serum and antibiotics (quiescent state) or were activated in the presence of interleukin 2 (20 units/mL, Roche Biochemicals, Indianapolis, Ind.) and phytohemagglutinin PHA-P (1 ⁇ g/mL, Sigma) for 3 to 4 days before the initiation of experiments.
  • interleukin 2 (20 units/mL, Roche Biochemicals, Indianapolis, Ind.
  • phytohemagglutinin PHA-P (1 ⁇ g/mL, Sigma
  • Human transformed CCRF-CEM T-cells were obtained from The American Type Culture Collection (Manassas, Va.) and cultured in RPMI-1640 medium supplemented with 10% FBS and antibiotics. An aliquot of cells (2 ⁇ 3 ⁇ 10 6 cells) was collected at each time point, counted, pelleted by centrifugation, resuspended in 0.5 mL of the original treatment media and layered onto 0.5 mL of Nyosil M25 oil. The samples were spun in a microcentrifuge for 20 seconds at the maximum speed (approximately 800 ⁇ g). The top layer of media was removed and the oil layer was washed twice with 0.8 mL phosphate-buffered saline.
  • Transient ion-pairing high-performance liquid chromatography coupled to positive ion electrospray tandem mass spectrometery was used to quantitate intracellular nucleotides.
  • Methods were adapted from those described for the acyclic phosphonate nucleotide analog adefovir, its phosphorylated metabolites and natural nucleotides (Vela, I. E. et al. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. Journal of Chromatography B Anal. Technol. Biomed.
  • Standard curves and quality control samples were generated for all analytes using extracts from untreated cells. Seven point standard curves generally ranged from 0.03 to 20 pmol/million cells and had linearity in excess of r 2 equal to 0.99 for all analytes. The lower limits of quantitations for all analytes ranged from 0.05 to 0.1 pmol/million cells. Low and high concentration quality control samples (typically 0.2 and 10 pmol/million cells, respectively) were run with each analyte at the beginning and end of each analytical run to assure accuracy and precision within 20%.
  • the parent compound was incubated at a 100-fold higher concentration (100 ⁇ M) than the prodrug (1 ⁇ M) to facilitate accurate analysis of the much lower intracellular accumulation of metabolites observed following incubation of lymphocytes with the parent compound.
  • the prodrug induced 76-, 290- and 140-fold increased levels of the active metabolite relative to the parent compound following incubation with CEM-CCRF, quiescent PBMCs and activated PBMCs, respectively. Active metabolite levels were normalized based on extracellular concentration following incubations with 1 ⁇ M prodrug or with 100 ⁇ M parent compound.
  • prodrug and “parent compound” have the meanings set forth in Example 8.
  • MT-2 cells were maintained in RPMI-1640 medium supplemented with antibiotics and 10% fetal bovine serum (FBS).
  • FBS fetal bovine serum
  • MT-2 cells were infected with HIV-1 IIIB at a multiplicity of infection (moi) of 0.01 and added to 96-well plates with serial dilutions of tested compounds at a density of 20,000 cells/well. After a 5-day incubation, the virus-induced cytopathic effect was determined using a CellTiter-GloTM cell viability assay (Promega, Madison, Wis.) and expressed as a percentage of the signal from samples with fully suppressed virus replication after the subtraction of signal from the untreated control.
  • moi multiplicity of infection
  • the concentration of each drug that inhibited the virus-induced cytopathic effect by 50% was determined by non-linear regression.
  • Activity against NRTI-resistant mutants was determined in parallel with wild-type control virus and fold change in EC 50 was calculated.
  • PBMC Human peripheral blood mononuclear cells
  • prodrug was 71- and 2,300-fold more potent than the parent compound in MT-2 and activated PBMC, respectively.
  • the dosing group consisted of 3 non-naive male beagle dogs. The animals were fasted overnight prior to dose administration and up to 4 hr after dosing. Dogs were administered a single tablet containing 41.38 mg of the citrate salt of the prodrug (providing 30 mg of the prodrug per tablet). The tablet consisted of 13.79% of the citrate salt of the prodrug, 66% anhydrous lactose, 15.21% microcrystalline cellulose, 3.5% sodium croscamellose and 1.5% magnesium stearate on a weight per weight basis. Plasma samples were obtained prior to dosing (0 hr) and at 0.083, 0.25, 0.50, 1.0, 2.0, 4.0, 8.0, 12, 24 hr.
  • the blood samples were collected into VacutainerTM tubes containing EDTA-K 3 .
  • the blood samples were centrifuged at 4° C. to separate plasma.
  • An aliquot of ⁇ l of each plasma sample was first diluted with 300 ⁇ l 80% acetonitrile/water containing 200 nM internal standard. Following centrifugation of the protein precipitate, 100 ⁇ l of the supernatant was removed and used for analysis.
  • Standard curves and quality control samples were prepared in dog plasma from animals not dosed with the prodrug. Samples were analyzed by a partially validated liquid chromatography couple to triple quadrupole mass spectrometry method.
  • Differential scanning calorimetry accurately measures temperatures and heat flow associated with thermal transitions in a material.
  • the DSC traces of the inventive salts of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]L-alaninate were generated using a TA Instrument (New Castle, Del.) DSC 2010 at a scan rate of 5° C. min ⁇ 1 .
  • FIG. 2 shows the characteristic DSC trace for the succinate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • FIG. 3 shows the characteristic DSC trace for the citrate salt of Ethyl N-[(S)( ⁇ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy ⁇ methyl)phenoxyphosphinoyl]-L-alaninate.
  • the citrate salt has a significantly greater heat of fusion than the malonate and succinate salts, indicating a higher degree of solid-state crystallinity.
  • XRPD X-ray powder diffraction
  • a Shimadzu XRD 6000 instrument with the following attributes was used: Cu X-ray tube, 2.2 KW, NF (normal focus); monochromator curved graphite; goniometer vertical, 185 mm radius; divergence slits: 0.5°, 1.0°, 0.05 mm; soller slits: 0.05°, 1°, 2°; receiving slits: 0.15 mm, 0.3 mm; scintillation detector (NaI) HV 500-1200.
  • a Shimadzu XRD 6000 instrument with the following attributes was used: Cu target X-ray tube, 35 kv, current 40 ma; continuous scan, monochromator, divergence slit, 1°; soller slit 1°, receiving slit 0.3 mm.
  • XRPD data for the malonate and succinate salts were obtained using method 1.
  • XRPD data for the citrate salt was obtained using method 2.
  • FIG. 4 shows the characteristic XRPD pattern for the malonate salt.
  • the principal and characteristic peaks that define this crystalline form of the malonate salt are shown in Tables 8A and 8B.
  • FIG. 5 shows the characteristic XRPD pattern for the succinate salt.
  • the principal and characteristic peaks that define this crystalline form of the succinate salt are shown in Tables 9A and 9B.
  • FIG. 6 shows the characteristic XRPD pattern for the citrate salt.
  • the principal and characteristic peaks that define this crystalline form of the citrate salt are shown in Tables 10A and 10B.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/499,018 2008-07-08 2009-07-07 Salts of hiv inhibitor compounds Abandoned US20100093667A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/499,018 US20100093667A1 (en) 2008-07-08 2009-07-07 Salts of hiv inhibitor compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7898908P 2008-07-08 2008-07-08
US12/499,018 US20100093667A1 (en) 2008-07-08 2009-07-07 Salts of hiv inhibitor compounds

Publications (1)

Publication Number Publication Date
US20100093667A1 true US20100093667A1 (en) 2010-04-15

Family

ID=41055429

Family Applications (6)

Application Number Title Priority Date Filing Date
US12/499,018 Abandoned US20100093667A1 (en) 2008-07-08 2009-07-07 Salts of hiv inhibitor compounds
US12/999,441 Active 2029-07-20 US8658617B2 (en) 2008-07-08 2009-07-07 Salts of HIV inhibitor compounds
US14/150,677 Active US8951986B2 (en) 2008-07-08 2014-01-08 Salts of HIV inhibitor compounds
US14/585,011 Active US9381206B2 (en) 2008-07-08 2014-12-29 Salts of HIV inhibitor compounds
US15/170,728 Active US9783568B2 (en) 2008-07-08 2016-06-01 Salts of HIV inhibitor compounds
US15/697,075 Abandoned US20180079772A1 (en) 2008-07-08 2017-09-06 Salts of hiv inhibitor compounds

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/999,441 Active 2029-07-20 US8658617B2 (en) 2008-07-08 2009-07-07 Salts of HIV inhibitor compounds
US14/150,677 Active US8951986B2 (en) 2008-07-08 2014-01-08 Salts of HIV inhibitor compounds
US14/585,011 Active US9381206B2 (en) 2008-07-08 2014-12-29 Salts of HIV inhibitor compounds
US15/170,728 Active US9783568B2 (en) 2008-07-08 2016-06-01 Salts of HIV inhibitor compounds
US15/697,075 Abandoned US20180079772A1 (en) 2008-07-08 2017-09-06 Salts of hiv inhibitor compounds

Country Status (26)

Country Link
US (6) US20100093667A1 (https=)
EP (1) EP2307435B1 (https=)
JP (2) JP5620376B2 (https=)
KR (1) KR101642527B1 (https=)
CN (1) CN102089318B (https=)
AP (1) AP3347A (https=)
AU (1) AU2009268681B2 (https=)
BR (1) BRPI0915878A2 (https=)
CA (1) CA2729769C (https=)
CL (1) CL2011000014A1 (https=)
CO (1) CO6321288A2 (https=)
CY (1) CY1113240T1 (https=)
DK (1) DK2307435T3 (https=)
EA (1) EA018308B1 (https=)
EC (1) ECSP11010807A (https=)
ES (1) ES2393962T3 (https=)
HR (1) HRP20120700T1 (https=)
IL (1) IL210006A (https=)
MX (1) MX2011000306A (https=)
NZ (1) NZ590075A (https=)
PE (1) PE20110219A1 (https=)
PL (1) PL2307435T3 (https=)
PT (1) PT2307435E (https=)
UA (1) UA103329C2 (https=)
WO (1) WO2010005986A1 (https=)
ZA (1) ZA201100694B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049754A1 (en) * 2004-07-27 2007-03-01 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US20110144050A1 (en) * 2008-07-08 2011-06-16 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
WO2012138907A3 (en) * 2011-04-05 2014-05-01 Translational Genomics Research Institute Solid forms of curcumin
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835932C (en) 2011-05-19 2020-03-24 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
WO2018064071A1 (en) * 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649041A (en) * 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
US5378474A (en) * 1989-01-06 1995-01-03 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6290994B1 (en) * 1995-04-12 2001-09-18 Decox, S.L. Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity
US20020156133A1 (en) * 1999-06-17 2002-10-24 Johannes Bartholomaeus Oral administration forms for administering a fixed tramadol and diclofenac combination
US20030045583A1 (en) * 2001-02-12 2003-03-06 American Home Products Corporation Novel succinate salt of O-desmethyl-venlafaxine
US20030149044A1 (en) * 2001-11-29 2003-08-07 Pfizer Inc. Succinic acid salts of 5,7,14-triazatetracyclo[10.1.02.11.04,9] -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6844349B2 (en) * 2001-12-12 2005-01-18 Pfizer Inc Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
US6872827B2 (en) * 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US20050202054A1 (en) * 2004-03-15 2005-09-15 Faryniarz Joseph R. Methods and compositions useful to prevent in-grown hair arising from shaving
US7084123B2 (en) * 2000-12-28 2006-08-01 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US20060223794A1 (en) * 2002-02-15 2006-10-05 Transform Phamaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20060281759A1 (en) * 2003-08-18 2006-12-14 De Diego Heidi L Succinate and malonate salt of trans 4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
US20070149552A1 (en) * 2005-12-16 2007-06-28 Wyeth Lyophilized compositions of a triazolopyrimidine compound
US20070149479A1 (en) * 2005-09-02 2007-06-28 Fischer Katrin C Nanoparticulate inclusion and charge complex for pharmaceutical formulations
US20070191482A1 (en) * 2005-01-06 2007-08-16 Cj Corporation Dicarboxylic acid salt of sibutramine
US20080221213A1 (en) * 2004-06-17 2008-09-11 Osteologix A/S Symbion Science Park Tablets Comprising a High Load of Strontium
US20080226731A1 (en) * 2005-05-10 2008-09-18 Madhav Vasanthavada Pharmaceutical Compositions Comprising I Matinib and a Release Retardant
US20080279932A1 (en) * 2005-08-04 2008-11-13 Jean-Louis Reber Compounds
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
DK159431C (da) * 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5455339A (en) * 1986-05-01 1995-10-03 University Of Georgia Research Foundation, Inc. Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
FR2611203B1 (fr) 1987-02-20 1989-06-09 Sturtz Georges Analogues gem-diphosphoniques d'amethopterine (methotrexate) et de derives deaza-n-10 amethopterine. leur preparation et les compositions pharmaceutiques qui les contiennent
JP2737191B2 (ja) * 1987-12-28 1998-04-08 東ソー株式会社 均質な石英ガラス塊の製造方法
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5466793A (en) * 1988-03-01 1995-11-14 Ajinomoto Co., Inc. Process for preparing 2', 3'- dideoxyinosine
ZA894534B (en) 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
US5744600A (en) * 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
JP2722673B2 (ja) 1989-05-31 1998-03-04 住友化学工業株式会社 光学活性なアシルビフェニル誘導体の製造法
DE4003574A1 (de) 1990-02-07 1991-08-08 Bayer Ag Neue dipeptide, verfahren zu ihrer herstellung und ihre verwendung als renininhibitoren in arzneimitteln
ATE131825T1 (de) 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
EP0465297B1 (en) 1990-07-04 1996-01-31 Merrell Dow Pharmaceuticals Inc. 9-Purinyl phosphonic acid derivatives
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
EP0468119A1 (en) 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
DE4111730A1 (de) 1991-04-10 1992-10-15 Knoll Ag Neue cytarabin-derivate, ihre herstellung und verwendung
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0531597A1 (en) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
DE4138584A1 (de) 1991-11-23 1993-05-27 Hoechst Ag Carbocyclische phosphonat-nucleotidanaloge, deren herstellung und verwendung
GB9126144D0 (en) 1991-12-10 1992-02-12 British Bio Technology Compounds
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
WO1995002582A1 (en) * 1993-07-14 1995-01-26 Ciba-Geigy Ag Cyclic hydrazine compounds
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
US5446137B1 (en) * 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5854227A (en) 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
RU2157368C2 (ru) 1994-09-26 2000-10-10 Сионоги Энд Ко., Лтд. Производные имидазола и фармацевтическая композиция на их основе
WO1996014314A2 (en) 1994-11-04 1996-05-17 Gilead Sciences, Inc. Thiepane compounds inhibiting and detecting hiv protease
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11508541A (ja) 1995-06-29 1999-07-27 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ二環式化合物
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
EP0852233A4 (en) 1995-09-21 1999-09-15 Nippon Shinyaku Co Ltd CYCLOSPORIN PHOSPHATE DERIVATIVES AND MEDICINAL COMPOSITION
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
RU2106353C1 (ru) 1996-03-19 1998-03-10 Корпорация "С энд Ти Сайенс энд Текнолоджи Инк." Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2
US5656746A (en) * 1996-03-28 1997-08-12 The Proctor & Gamble Company Temporary wet strength polymers from oxidized reaction product of polyhydroxy polymer and 1,2-disubstituted carboxylic alkene
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
CA2261619C (en) 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
US6194398B1 (en) 1996-08-13 2001-02-27 Mitsubishi Chemical Corporation Phosphonate nucleotide compound
EP0948341A4 (en) 1996-09-17 2003-05-21 Supergen Inc DERIVATIVES OF PHOSPHOLIPIDE MEDICINES
JP4118958B2 (ja) 1996-10-09 2008-07-16 ファーマセット，リミティド テトラホスホネート二環式トリス無水物
JP3378016B2 (ja) * 1996-12-26 2003-02-17 塩野義製薬株式会社 カルバモイル基を有するイミダゾール誘導体の製造法
WO1999029702A2 (en) 1997-12-10 1999-06-17 The Government Of The United States Of America Reppresented By The Secretary, Department Of Health And Human Services METHOD FOR SYNTHESIZING 9-(2,3-DIDEOXY-2-FLUORO-β-D-THREO-PENTOFURANOSYL)ADENINE (β-FddA)
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6174888B1 (en) * 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
AU4125099A (en) 1998-06-01 1999-12-20 S & T Science And Technology Inc. Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
TWI260322B (en) * 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
HUP0200260A3 (en) 1999-03-05 2002-11-28 Metabasis Therapeutics Inc San Novel phosphorus-containing prodrugs, their preparation and their use
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
CA2377278C (en) * 1999-06-25 2010-03-23 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
US6581606B2 (en) * 1999-07-06 2003-06-24 The Rx Files Corporation Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
GB9920872D0 (en) 1999-09-04 1999-11-10 Glaxo Group Ltd Benzophenones as inhibitors of reverse transcriptase
IL131887A0 (en) 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
DE60038038T2 (de) 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
WO2001046204A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
WO2001064693A1 (fr) 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Compose de nucleotide de phosphonate
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153363A0 (en) 2000-06-13 2003-07-06 Shionogi & Co Pharmaceutical compositions containing propenone derivatives
FR2810322B1 (fr) 2000-06-14 2006-11-10 Pasteur Institut PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6617310B2 (en) 2000-07-19 2003-09-09 Bristol-Myers Squibb Pharma Company Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines
CZ304734B6 (cs) 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
US6420586B1 (en) 2000-08-15 2002-07-16 University Of Kansas Amino acid-derived cyclic phosphonamides and methods of synthesizing the same
WO2002020010A1 (en) * 2000-09-08 2002-03-14 Zeria Pharmaceutical Co., Ltd. Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions
RU2188203C2 (ru) 2000-10-05 2002-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" 2',3'-дидегидро-2',3'-дидезокситимидин-5'[(этоксикарбонил)(этил)фосфонат]- ингибитор репродукции вируса иммунодефицита человека
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
MXPA03005403A (es) * 2001-01-31 2003-09-25 Warner Lambert Co Metodo para carbamoilar alcoholes.
US6962684B2 (en) * 2001-05-31 2005-11-08 Sumitomo Chemical Company, Limited Activated alumina formed body and method for producing the same
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
ATE371026T1 (de) 2001-06-20 2007-09-15 Nuevolution As Eine methode zur synthese von matrizenabhängigen molekülen
KR20020097384A (ko) * 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
ATE411805T1 (de) * 2001-07-20 2008-11-15 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
KR100879693B1 (ko) * 2001-08-17 2009-01-21 상꾜 아그로 가부시키가이샤 2-시클로프로필-6-메틸페놀
WO2003028737A1 (en) 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
AU2002343556A1 (en) 2001-12-07 2003-06-23 Eli Lilly And Company Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
KR101016969B1 (ko) 2001-12-21 2011-02-25 에이자이 아이엔씨. 알콜 및 페놀의 수용성 포스포노옥시메틸 유도체를제조하는 방법
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
EP1472230B1 (en) 2002-02-08 2009-06-17 Conforma Therapeutic Corporation Ansamycins having improved pharmacological and biological properties
WO2003080078A1 (en) 2002-03-18 2003-10-02 Mitsubishi Pharma Corporation Treatment of pre-core hepatitis b virus mutant infections
WO2003087090A2 (en) * 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical,Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US6808572B2 (en) * 2002-05-15 2004-10-26 Aerojet-General Corporation Solid propellant formulations and methods and devices employing the same for the destruction of airborne biological and/or chemical agents
EP1546138B1 (en) 2002-09-30 2012-01-18 A/S GEA Farmaceutisk Fabrik Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes
US20040157793A1 (en) * 2002-11-12 2004-08-12 Stuyver Lieven J. Modified nucleosides as antiviral agents
EA012844B1 (ru) * 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
WO2004100960A2 (en) 2003-04-25 2004-11-25 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7273716B2 (en) 2003-04-25 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-7340 ester hydrolase
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
EP2359833A1 (en) 2003-04-25 2011-08-24 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096235A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
NZ542343A (en) 2003-04-25 2009-03-31 Gilead Sciences Inc Immunomodulator phosphonate conjugates
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2004096237A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005000786A1 (en) 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
EP1634882A4 (en) * 2003-06-16 2008-01-09 Ajinomoto Kk INOSIN DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
AU2004260789B2 (en) 2003-07-30 2011-06-30 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005063751A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. 4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity
CA2548951A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US20050171126A1 (en) * 2003-12-26 2005-08-04 Ajinomoto Co., Inc. Process for the production of purine nucleoside compounds
ME03423B (me) * 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
WO2006015262A2 (en) 2004-07-29 2006-02-09 Coherix, Inc. Method for processing multiwavelength interferometric imaging data
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7154505B2 (en) 2004-11-11 2006-12-26 Stonecube Limited Method of and apparatus for generating a representation of an object
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
JP5243413B2 (ja) * 2006-05-26 2013-07-24 スリーディー システムズ インコーポレーテッド ３次元プリンターで材料を処理する装置と方法
PL3150586T3 (pl) * 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
UA103329C2 (ru) * 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
JP4330086B1 (ja) 2009-02-09 2009-09-09 株式会社テクネス 非酸化物セラミックス製品の製造方法
EP2305680A3 (en) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
WO2014055618A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
US20140094609A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649041A (en) * 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
US5378474A (en) * 1989-01-06 1995-01-03 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US6290994B1 (en) * 1995-04-12 2001-09-18 Decox, S.L. Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6602902B2 (en) * 1996-05-22 2003-08-05 Protarga, Inc. Dha-pharmaceutical agent conjugates to improve tissue selectivity
US20020156133A1 (en) * 1999-06-17 2002-10-24 Johannes Bartholomaeus Oral administration forms for administering a fixed tramadol and diclofenac combination
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7084123B2 (en) * 2000-12-28 2006-08-01 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
US20030045583A1 (en) * 2001-02-12 2003-03-06 American Home Products Corporation Novel succinate salt of O-desmethyl-venlafaxine
US20030149044A1 (en) * 2001-11-29 2003-08-07 Pfizer Inc. Succinic acid salts of 5,7,14-triazatetracyclo[10.1.02.11.04,9] -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
US6844349B2 (en) * 2001-12-12 2005-01-18 Pfizer Inc Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
US20060223794A1 (en) * 2002-02-15 2006-10-05 Transform Phamaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US6872827B2 (en) * 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US20060281759A1 (en) * 2003-08-18 2006-12-14 De Diego Heidi L Succinate and malonate salt of trans 4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
US20050202054A1 (en) * 2004-03-15 2005-09-15 Faryniarz Joseph R. Methods and compositions useful to prevent in-grown hair arising from shaving
US20080221213A1 (en) * 2004-06-17 2008-09-11 Osteologix A/S Symbion Science Park Tablets Comprising a High Load of Strontium
US20070191482A1 (en) * 2005-01-06 2007-08-16 Cj Corporation Dicarboxylic acid salt of sibutramine
US20080226731A1 (en) * 2005-05-10 2008-09-18 Madhav Vasanthavada Pharmaceutical Compositions Comprising I Matinib and a Release Retardant
US20080279932A1 (en) * 2005-08-04 2008-11-13 Jean-Louis Reber Compounds
US20070149479A1 (en) * 2005-09-02 2007-06-28 Fischer Katrin C Nanoparticulate inclusion and charge complex for pharmaceutical formulations
US20070149552A1 (en) * 2005-12-16 2007-06-28 Wyeth Lyophilized compositions of a triazolopyrimidine compound
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs
US9139604B2 (en) 2003-04-25 2015-09-22 Gilead Sciences, Inc. Antiviral phosphonate analogs
US8697861B2 (en) 2004-07-27 2014-04-15 Gilead Sciences, Inc. Antiviral compounds
US20090012037A1 (en) * 2004-07-27 2009-01-08 Gilead Science, Inc. Antiviral Compounds
US9579332B2 (en) 2004-07-27 2017-02-28 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US8318701B2 (en) 2004-07-27 2012-11-27 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US8329926B2 (en) 2004-07-27 2012-12-11 Gilead Sciences, Inc. Antiviral compounds
US7871991B2 (en) * 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US20070049754A1 (en) * 2004-07-27 2007-03-01 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
US9457035B2 (en) 2004-07-27 2016-10-04 Gilead Sciences, Inc. Antiviral compounds
US20090202470A1 (en) * 2004-07-27 2009-08-13 Gilead Sciences, Inc. Phosphonate Analogs of Hiv Inhibitor Compounds
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US8951986B2 (en) 2008-07-08 2015-02-10 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US9381206B2 (en) 2008-07-08 2016-07-05 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US20110144050A1 (en) * 2008-07-08 2011-06-16 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
US9783568B2 (en) 2008-07-08 2017-10-10 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
US9447050B2 (en) 2011-04-05 2016-09-20 The Translational Genomics Research Institute Solid forms of curcumin
WO2012138907A3 (en) * 2011-04-05 2014-05-01 Translational Genomics Research Institute Solid forms of curcumin
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate

Also Published As

Publication number Publication date
NZ590075A (en) 2012-12-21
EA201071367A1 (ru) 2011-08-30
AU2009268681A1 (en) 2010-01-14
CN102089318A (zh) 2011-06-08
US20140227224A1 (en) 2014-08-14
US20150182547A1 (en) 2015-07-02
IL210006A (en) 2016-02-29
CO6321288A2 (es) 2011-09-20
IL210006A0 (en) 2011-02-28
JP5620376B2 (ja) 2014-11-05
PT2307435E (pt) 2012-09-19
CY1113240T1 (el) 2016-04-13
AP2010005509A0 (en) 2010-12-31
US20110144050A1 (en) 2011-06-16
EP2307435B1 (en) 2012-06-13
US9381206B2 (en) 2016-07-05
EA018308B1 (ru) 2013-07-30
AU2009268681B2 (en) 2014-10-02
UA103329C2 (ru) 2013-10-10
ECSP11010807A (es) 2011-09-30
US9783568B2 (en) 2017-10-10
MX2011000306A (es) 2011-03-15
ZA201100694B (en) 2013-04-24
DK2307435T3 (da) 2012-09-10
PL2307435T3 (pl) 2012-11-30
CL2011000014A1 (es) 2011-05-13
US20180079772A1 (en) 2018-03-22
AP3347A (en) 2015-07-31
US8951986B2 (en) 2015-02-10
KR20110029165A (ko) 2011-03-22
JP2011527687A (ja) 2011-11-04
US8658617B2 (en) 2014-02-25
BRPI0915878A2 (pt) 2015-11-03
HRP20120700T1 (hr) 2012-09-30
HK1156633A1 (en) 2012-06-15
ES2393962T3 (es) 2013-01-03
PE20110219A1 (es) 2011-03-31
EP2307435A1 (en) 2011-04-13
JP2014122235A (ja) 2014-07-03
CA2729769A1 (en) 2010-01-14
KR101642527B1 (ko) 2016-07-25
WO2010005986A1 (en) 2010-01-14
US20160355543A1 (en) 2016-12-08
CN102089318B (zh) 2014-05-21
CA2729769C (en) 2017-09-05

Similar Documents

Publication Publication Date Title
US9783568B2 (en) Salts of HIV inhibitor compounds
USRE46762E1 (en) 1′-substituted carba-nucleoside analogs for antiviral treatment
US8415308B2 (en) 1′-substituted-carba-nucleoside prodrugs for antiviral treatment
US20110223131A1 (en) Antiviral compounds
AU2016250419B2 (en) 1' -substituted carba-nucleoside analogs for antiviral treatment
HK1156633B (en) Salts of hiv inhibitor compounds
AU2013216595B2 (en) 1' -substituted carba-nucleoside analogs for antiviral treatment

Legal Events

Date Code Title Description
AS Assignment

Owner name: GILEAD SCIENCES, INC.,CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAETZ, BENJAMIN R.;POLNIASZEK, RICHARD P.;SIGNING DATES FROM 20090902 TO 20090908;REEL/FRAME:023322/0470

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION